Back to top
more

BioLineRx (BLRX)

(Delayed Data from NSDQ)

$0.45 USD

0.45
300,511

0.00 (-0.35%)

Updated Nov 7, 2024 03:59 PM ET

After-Market: $0.45 0.00 (-0.31%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Drugs

Zacks News

Aclaris Stock Up on JAK Inhibitor's Encouraging Activity

Aclaris Therapeutics (ACRS) posts positive interim data from a phase II study on its Alopecia Areata candidate, ATI-502.

    BioLineRx Sees Hammer Chart Pattern: Time to Buy?

    BioLineRx Sees Hammer Chart Pattern: Time to Buy?

      Shire (SHPG) HAE Drug Gets FDA Nod for Pediatric Population

      Shire (SHPG) gains FDA approval for expanding the label of its hereditary angioedema (HAE) drug, Cinryze, to include its usage among pediatric patients aged six years and older.

        Moving Average Crossover Alert: BioLineRx Ltd. (BLRX)

        Moving Average Crossover Alert: BioLineRx Ltd. (BLRX)

          BioLineRx Cancer Drug Positive as Monotherapy in Phase IIa

          BioLineRx (BLRX) posts encouraging partial results from the monotherapy portion of a phase IIa COMBAT study, assessing its lead pipeline candidate, BL-8040, for pancreatic cancer patients.

            BioLineRx/Roche Scan BL-8040-Tecentriq for Gastric Cancer

            BioLineRx (BLRX) and partner Genentech initiate a phase Ib/II study to evaluate the company's lead pipeline candidate, BL-8040, in combination with Tecentriq for treating gastric cancer.

              BioLineRx Moves a Regulatory Submission for BL-8040 Trial

              BioLineRx (BLRX) forwards a regulatory submission to begin a phase III study to evaluate BL-8040 in combination with G-CSF for treatment of multiple myeloma.

                BioLine Rx (BLRX) Catches Eye: Stock Adds 5.2% in Session

                BioLine Rx Ltd (BLRX) shares rise over 5% in the last trading session.

                  BioLineRx/Roche Scan BL-8040-Tecentriq for Pancreatic Cancer

                  BioLineRx Ltd. (BLRX) announced that its partner Genentech, has initiated a phase Ib/II study, evaluating BL-8040 in combination Tecentriq (atezolizumab) for treatment of patients with metastatic pancreatic ductal adenocarcinoma.

                    BioLineRx Makes Regulatory Submission for Trial of BL-8040

                    BioLineRx Ltd. (BLRX) announced that it has submitted a regulatory filing required to start a phase Ib study for BL-8040 in combination with Roche Group's (RHHBY) Tecentriq (atezolizumab).

                      BioLineRx (BLRX) Starts Cancer Study on BL-8040+Keytruda

                      BioLineRx (BLRX) announced the initiation of a second phase IIa study on BL-8040 in combination with Keytruda for the treatment of pancreatic cancer.